0.60Open0.85Pre Close1 Volume39 Open Interest8.00Strike Price60.00Turnover116.23%IV15.81%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.60Extrinsic Value100Contract SizeAmericanOptions Type-0.3147Delta0.1415Gamma14.65Leverage Ratio-0.0200Theta-0.0019Rho-4.61Eff Leverage0.0077Vega
Terns Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Terns Pharmaceuticals(TERN.US)$
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
Terns Pharmaceuticals announced new preclinical data supporting their compound TERN-501 in combination with a GLP-1 receptor agonist for treating obesity. The data was presented at the ADA’s 84th Annual Scientific Sessions. TERN-501, a highly selective THR-...
Larger Image: tradingview.com...
$Terns Pharmaceuticals(TERN.US)$
Larger Image: tradingview.com...
$Terns Pharmaceuticals(TERN.US)$
NEWS
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
Larger Image: tradingview.com...
$Terns Pharmaceuticals(TERN.US)$
Larger Image: tradingview.com...
$Terns Pharmaceuticals(TERN.US)$
No comment yet